Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dicerna

Roche Basel Switzerland

Roche presents new data in NMOSD, could challenge Alexion’s Soliris

Reduced risk of relapse by 55%

- PMLiVE

Amgen takes aim at Alexion’s patents for Soliris

Follows extension of Soliris patent protection until 2027

- PMLiVE

Alexion’s Soliris adds new approval in rare disease NMOSD

First ever drug approved for rare autoimmune disease

- PMLiVE

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Opioid dependence therapy and Pfizer's PARP inhibitor also recommended

- PMLiVE

Alexion targets RNAi with $637m Dicerna deal

Bolsters pipeline ahead of Soliris patent protection loss

- PMLiVE

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines

- PMLiVE

Alexion adds to pipeline with $1.2bn Syntimmune buy

As company prepares for possible loss of patent protection for Soliris

- PMLiVE

Alexion uses priority review voucher for Soliris follow-up

Files ravulizumab for paroxysmal nocturnal haemoglobinuria

- PMLiVE

Morning brief: Sanofi’s shaky start, pharma begins talks with UK government and more

Sanofi falling behind in Amgen cholesterol battleFirst quarter results from Sanofi show the company has got off to shaky start in 2018, including signs that it its PCKS9 inhibitor cholesterol...

- PMLiVE

Alexion adds to pipeline rebuild with $855m Wilson buy

Also acquires the Swedish group’s lead product for Wilson’s disease

- PMLiVE

Alexion appoints new senior VP for EMEAC region

Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland

- PMLiVE

Boehringer bolsters NASH pipeline with $201m Dicerna deal

Will investigate a “new therapeutic approach” to target liver functionality

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links